Physician

Juliet M Penn, M.D.

According to 2025 Medicare claims, Juliet Penn, M.D. (NPI: 1215175070) practices medical oncology in the Santa Maria-Santa Barbara, CA market, with the plurality of this provider's patient population coming from Santa Barbara, CA. This provider's primary affiliated billing organization is THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (NPI: 1235107566; TIN: 954373071) and primary practice location at 93101-2018. Penn is affiliated with the Aledade A3299 CA MSSP Enhanced (ACO ID: A3299), participating under the MSSP model.

Penn's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 502 traditional Medicare patients, billed 137,509 HCPCS/CPT codes, and received $2,406,765 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 529 prescription claims across 122 beneficiaries totaling $1,193,328 in drug costs, led by Verzenio (Abemaciclib). 2022 DME data shows 28 claims. Open Payments data shows 7 records totaling $243. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $509,906 to $2,406,765. In contrast, Part D prescription costs have risen steadily, from $172,182 to $1,193,328. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $1,686 and ending at $1,784.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	205	55,849	$509,906
2016	298	137,589	$1,037,943
2017	318	112,686	$1,359,281
2018	344	130,052	$1,647,882
2019	422	158,479	$2,519,523
2020	389	103,687	$1,530,978
2021	447	117,534	$1,602,302
2022	373	54,150	$746,978
2023	263	48,116	$844,792
2024	502	137,509	$2,406,765

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	64	223	$172,182
2016	103	580	$191,817
2017	145	917	$379,513
2018	146	1,013	$688,650
2019	144	887	$1,189,728
2020	129	870	$1,578,926
2021	129	772	$1,787,510
2022	114	520	$1,214,710
2023	65	326	$437,658
2024	122	529	$1,193,328

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	196	$72,945
2018	N/R	48	$6,548
2019	N/R	39	$4,219
2020	N/R	24	$1,294
2021	N/R	N/R	N/R
2022	N/R	28	$1,541
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	143	143	$134
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	337	1,046	$104
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	232	433	$13
36415	Insertion of needle into vein for collection of blood sample	115	246	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	123	329	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	18	504	$299,299
Iclusig	Ponatinib Hcl	11	330	$236,777
Eliquis	Apixaban	12	360	$6,836
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	374	$685
Letrozole	Letrozole	12	870	$641

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$243	Sumitomo Pharma America, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Juliet M. Penn, M.D.?

Tedicare shows public-source Medicare data for Juliet M. Penn, M.D. (NPI 1215175070), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Juliet M. Penn, M.D. have ACO affiliation data?

Juliet M. Penn, M.D. is shown with ACO affiliation data for Aledade A3299 CA MSSP Enhanced (MSSP, ACO ID A3299).

What billing organization is linked to Juliet M. Penn, M.D.?

Juliet M. Penn, M.D. is linked to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (billing NPI 1235107566) in the available physician profile data.

Does Juliet M. Penn, M.D. have Open Payments data?

Juliet M. Penn, M.D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.